There was no significant reduction in risk of SCD in patients using PCSK9 inhibitors as compared to controls but with a trend favoring treatment (RR 0.83, 95% CI 0.54–1.28; P = 0.40; Fig 3). Here, PCSK9 is linked to Schnyder corneal dystrophy.